Abstract
ABSTRACT Stereotactic arrhythmia radioablation for ventricular tachycardia has been recently introduced into clinical practice. Evidence for this treatment is highly limited, however, it has shown potential for severe refractory disease. We add to the limited body of evidence detailing our experience with our first patients. Both were treated using a similar workflow as described in the existing literature with 25 Gy prescribed to the VT substrate. Additionally, we contoured and evaluated dose to cardiac subtructures to document and follow radiation toxicity. Both patients initially showed a significant decrease in VT events and defibrillator shock burden, however one has relapsed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
